This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.There is a growing body of evidence indicating that chronic hyperactivation of the immune system represents a fundamental mechanism of HIV/AIDS pathogenesis. Using a rhesus macaque model of human HIV infection, this study aims to provide a conclusive demonstration that excess activation and proliferation of immune cells in response to chronic HIV stimulation causes AIDS. SIV-infected rhesus macaques will be treated with either the cytostatic drug hydroxyurea or a placebo, and periodically evaluated for immunological and virological parameters. It is hypothesized that animals treated with hydroxyurea will have reduced immune activation and longer survival rates than control animals, even though viral loads are expected to be similar. This study is currently in the very beginning stages of data collection. However, if it is demonstrated that cytostatic drugs prevent the onset of AIDS and delay death, the potential impact upon the future of AIDS therapy would be significant.
Showing the most recent 10 out of 912 publications
